An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
Myllylä
V V
VV
Department of Neurology, University Central Hospital, Oulu, Finland.
Sotaniemi
K A
KA
Aasly
J
J
Sjaastad
O
O
Rinne
U
U
McIntyre
T
T
Cremer
G
G
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000498:Allyl Compounds; D002082:Butylamines / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009043:Motor Activity / Q000187:drug effects; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology
D000498:Allyl Compounds; D002082:Butylamines; D008996:Monoamine Oxidase Inhibitors; C058000:mofegiline